Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Bacterial Infections Clinical Trials

A listing of Bacterial Infections medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (15) clinical trials

This is a study to assess the pharmacokinetics (PK) of tedizolid phosphate and its active metabolite, tedizolid, and the safety of tedizolid phosphate following administration of a single IV (Part A) or oral suspension (Part B) administration to hospitalized participants ages 6 to less than 12 years (Groups 1 and ...

Phase

The goal of this study is to compare changes in the female genital tract in women diagnosed with bacterial vaginosis (BV) before and after treatment and to compare differences in the female genital tract in adolescent and adult women. Women with BV have an increased risk of acquiring HIV and ...

Phase

Dose-finding Pharmacokinetics Safety and Tolerability of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects With Serious Bacterial Infections

In the current era of increased resistance to extended spectrum cephalosporins, carbapenem antimicrobial agents are frequently the antibiotics of "last defense" for the most resistant pathogens in serious infections, including those found in complicated Urinary Tract Infections (cUTI). The recent dissemination of serine carbapenemases (e.g. KPC) in Enterobacteriaceae in many ...

Phase

A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study

This is a phase 1, single-center, randomized, placebo-controlled, double-blind, multiple ascending-dose study to assess the safety, tolerability, and PK of oral TP-271 in healthy adult subjects. Male or female subjects aged 18 to 50 years who fulfill the inclusion/exclusion criteria will be enrolled in this study. Up to 5 cohorts ...

Phase

11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects

Patients with suspected bacterial infection at the time screening are eligible for this study. Patients may participate in this study if they are at least 18 years of age, and most participants will be receiving care at the clinical practices of the University of Pennsylvania. Up to 30 subjects will ...

Phase

Study Evaluate the PK Profile of Dalbavancin in Hospitalized Infants and Neonates Patients With Known or Suspected Bacterial Infection

The purpose of this study is to evaluate the Pharmacokinetic (PK) profile of a single intravenous (IV) infusion dose of dalbavancin, and to evaluate the safety and tolerability of a single dalbavancin IV infusion.

Phase

Prevention of Preterm Infection by Autologous Umbilical Cord Blood Mononuclear Cells Therapy

This is a Phase 1 clinical trial that constitutes two time points cohorts with 80 participants per cohort who will receive intravenous doses of Autologous Umbilical Cord Blood Mononuclear Cells --25 million cells/kg,6 hours or 48 hours after birth. And the placebo will be 0.9% sodium chloride.The investigator will proceed ...

Phase

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

This study aims to obtain plasma pharmacokinetic (PK) data and characterize the PK profile of imipenem (IMI), cilastatin (CIL), and relebactam (REL) following administration of a single intravenous (IV) dose of MK-7655A (a fixed ratio combination of imipenem/cilastatin/relebactam), hereafter referred to as IMI/REL.

Phase

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

The primary objective is to characterize the pharmacokinetics of single doses of ceftobiprole in neonates and infants aged 3 months. The secondary objective is to evaluate safety and tolerability of ceftobiprole in neonates and infants aged 3 months.

Phase

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants Ages 2 to <12 Years With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Part A (IV): Group 1 (Cohort 1 and Cohort 2) (6 to <12 years) Group 2 (Cohort 1 and Cohort 2) (2 to <6 years) Part B (Oral Suspension): Group 3 (6 to <12 years) Group 4 (2 to <6 years) In Cohort 1 of Group 1 (IV) participants received ...

Phase